• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy.
【24h】

Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy.

机译：干扰素beta治疗期间复发缓解和继发进行性多发性硬化症患者的神经营养因子。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Although interferon (IFN) beta is a widely used disease-modifying therapy in multiple sclerosis (MS), the mechanisms responsible for its effects are not fully understood. Some studies demonstrated that IFNbeta induces nerve growth factor (NGF) secretion by astrocytes and by brain endothelial cells. In this study, we determined the production of various neurotrophins (brain-derived neurotrophic factor, BDNF; NGF; glial cell line-derived neurotrophic factor; neurotrophin 3; neurotrophin 4) by peripheral blood mononuclear cells (PBMCs) in relapsing-remitting (RR) and secondary progressive (SP) MS patients during IFNbeta treatment. There were no main variations in neurotrophin production either among all MS patients globally considered or in the group of SPMS subjects. Instead, in the group of RRMS patients who did not present clinical exacerbation of disease up to the end of the study, we found a significant increase in BDNF production as from 6 months after starting therapy.
机译：尽管干扰素（IFN）β是多发性硬化症（MS）中广泛使用的疾病缓解疗法，但对其作用机理尚未完全了解。一些研究表明，IFNβ诱导星形胶质细胞和脑内皮细胞分泌神经生长因子（NGF）。在这项研究中，我们确定了复发-释放（RR）的外周血单核细胞（PBMC）产生的各种神经营养蛋白（脑源性神经营养因子，BDNF; NGF;神经胶质细胞系神经营养因子;神经营养蛋白3;神经营养蛋白4）的产生。 ）和IFNbeta治疗期间的继发进行性（SP）MS患者。在全球考虑的所有MS患者中或在SPMS患者组中，神经营养蛋白的产生均无主要变化。取而代之的是，在研究结束之前未表现出临床病情恶化的RRMS患者组中，我们发现从开始治疗后的6个月开始，BDNF的产生显着增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号